Daiichi Sankyo boasts ‘steady and sustained growth’

Daiichi Sankyo has reported that it is experiencing a period of growth, with expansion of its staffing and facilities, which it claims is in contrast with the downsizing of a number of its competitors in the industry.

The company states that this growth is supporting its increasing drug development pipeline in the fields of cardiovascular disease, diabetes, infection and oncology, with the business now approaching mid-sized company status.

Daiichi Sankyo was formed in 2006 following the merger of Sankyo and Daiichi in the US in that year.

Joseph P Pieroni, president and chief executive officer of Daiichi Sankyo, said: “Over the next three years, we expect to achieve a 60 per cent growth in sales.

“The legacy of Daiichi and Sankyo is more than a century of pharmaceutical experience in bringing important medical discoveries to market.”

He added that the company is continuing those firms’ history of robust innovation in research and development, expressing confidence that the business is well-positioned to become a leading firm in the field of cardiovascular care and succeed in the US.

Last year, Daiichi Sankyo announced a restructure of its group companies with the aim of maximising its corporate value and realising higher levels of growth to maintain competitiveness and develop novel pharmaceutical products.